News

FDA Approves Nivolumab for Treatment of Certain Patients With ESCC

06/11/2020

The FDA has approved nivolumab for the treatment of certain patients with unresectable advanced, recurrent, or metastatic esophageal squamous cell carcinoma (ESCC).

The FDA has approved nivolumab...

06/11/2020

Oncology

News

Camrelizumab Improves OS Over Chemo in Esophageal Squamous Cell Carcinoma

05/25/2020

Phase 3 study findings suggest that second-line camrelizumab significantly improves OS in patients with advanced or metastatic esophageal squamous cell carcinoma.

Phase 3 study findings suggest...

05/25/2020

Oncology

News

Experts Create Instrument to Measure Functional Outcomes in Head and Neck Cancer

05/12/2020

The Edmonton-33 instrument could serve as a single all-inclusive measure for functional outcomes in patients with head and neck cancer.

The Edmonton-33 instrument could...

05/12/2020

Oncology

News

Nomogram Predicts Delayed Postsurgery RT Initiation in HNSCC

05/06/2020

A nomogram that generates individualized estimates of PORT initiation delay in patients with HNSCC could improve pretreatment counseling and intervention.

A nomogram that generates...

05/06/2020

Oncology

News

Osimertinib a Potential Treatment Option for Intracranial Metastatic Disease

04/28/2020

Study findings support the use of osimertinib in the management of patients with intracranial metastatic disease.

Study findings support the use...

04/28/2020

Oncology

News

FDG PET/CT Parameters Yield Prognostic Value After Surgery for HNSCC

04/13/2020

Study findings posit using FDG-PET/CT parameters to identify patients with HNSCC and a higher risk for disease progression postsurgery who could benefit from early therapeutic intensification.

Study findings posit using...

04/13/2020

Oncology

News

Scoring System Predicts 90-Day Mortality of Patients With Locally Advanced HNSCC

04/13/2020

A scoring system has accurately predicted the 90-day mortality of >16,000 patients with locally advanced HNSCC who completed concurrent CRT.

A scoring system has accurately...

04/13/2020

Oncology

News

Bemarituzumab Safe, Active for Advanced Gastroesophageal Cancer

04/06/2020

Bemarituzumab was well-tolerated as late-line therapy in patients with advanced FGFR2b-overexpressing gastric and gastroesophageal junction adenocarcinoma in a dose-escalation study.

Bemarituzumab was well-tolerated...

04/06/2020

Oncology

News

Increase in Aggressive Papillary Thyroid Carcinomas Calls for Tailored Therapies

03/20/2020

Researchers stress the importance of tailoring therapies for disproportionately increasing subtypes of aggressive papillary thyroid carcinomas.

Researchers stress the...

03/20/2020

Oncology

News

HPV Status Impacts Therapy Decisions for Barrett HGD and Esophageal Cancer

03/03/2020

Therapy for patients with Barrett high-grade dysplasia (HGD) and esophageal adenocarcinoma may be personalized depending on their HPV status.

Therapy for patients with...

03/03/2020

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology